)
Bora Pharmaceuticals (6472) investor relations material
Bora Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic growth and global expansion
Achieved 700% market cap growth since 2017, surpassing $2 billion, through organic growth and strategic acquisitions, including Upsher-Smith, Pyros, Emergent's sterile fill and finish facility, and Tanvex, expanding U.S. and biologics capabilities.
Operates 10 manufacturing sites (5 in North America, 5 in Taiwan), exporting to 100+ countries, with 95% of revenue from outside Taiwan and a strong focus on North America.
Became the first Taiwanese company to join the U.S. OTCQX market, enhancing global visibility and investor access, with cross-market trading starting in 2026.
Re-signed multi-year commercial contracts, including a $350 million deal, and made record CapEx and sales/marketing investments in 2025.
Integrated Tanvex BioPharm as Bora Biologics, completing full-service CDMO capabilities in both small and large molecules and entering the large molecule sector.
Operational and financial performance
Fiscal 2025 revenue reached $634 million, with 3Q25 revenue at $195 million; net income from continuing operations was $129 million.
CDMO business grew 53.8% year-over-year to over $340 million, with a 96% OTIF rate and improved efficiency.
EBITDA margin rose to 40% in 2024 from 17% in 2017, with steady ROIC expansion and a focus on value creation.
Discontinued nonprofitable operations, reducing net working capital utilization from 53% to 23.69% and freeing up capital for investment.
Maintained strong cash positions, increased CapEx, paid dividends, and kept a consistent debt-to-EBITDA ratio.
Investments and capacity enhancements
Invested $400 million in U.S. CapEx over two years, focusing on organic growth, integration post-acquisition, and major investments in aseptic technologies and new filling lines across US, Canada, and Taiwan.
Maryland site received a city lab permit in Dec. 2025; cleanroom construction and validation batches scheduled for 2026.
Canadian facility increased derma product capacity by 40%, supporting a dermatology market projected to double by 2030.
New liquid-filled hard capsule capability in Taiwan to be operational in 1Q26, targeting oncology and potent drugs.
Expanded aseptic fill and finish and biologics capabilities in the U.S., with new lines and technologies coming online in 2025–2026.
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
Next Bora Pharmaceuticals earnings date
Next Bora Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)